Quality of life and metabolic status in mildly depressed women with type 2 diabetes treated with paroxetine: A single-blind randomised placebo controlled trial

被引：61

作者：

Maria Paile-Hyvärinen

Kristian Wahlbeck

Johan G Eriksson

机构：

[1] Department of Psychiatry, University of Helsinki, Lapinlahti Hospital, FIN-00029 HUCH, Helsinki

[2] National Public Health Institute, FIN-00300 Helsinki

[3] Natl. Res./Devmt. Ctr. Welf./Hlth., STAKES, FIN-00531 Helsinki

[4] Vaasa Central Hospital, Vaasa

来源：

BMC Family Practice | / 4卷 / 1期

关键词：

Glycemic Control; Paroxetine; Improve Insulin Sensitivity; Antidiabetic Medication; Serum Cortisol Level;

D O I：

10.1186/1471-2296-4-7

中图分类号：

学科分类号：

摘要：

Background: Depression is prevalent in people with type 2 diabetes and affects both glycemic control and overall quality of life. The aim of this trial was to evaluate the effect of the antidepressant paroxetine on metabolic control, quality of life and mental well-being in mildly depressed women with type 2 diabetes. Methods: We randomised 15 mildly depressed women with non-optimally controlled type 2 diabetes to a 10-week single-blind treatment with either paroxetine 20 mg per day or placebo. Primary efficacy measurements were glycemic control and quality of life. Glycosylated hemoglobin A 1c (GHbA1c) was used as a measure of glycemic control. Quality of life was evaluated using RAND-36. Mental state was assessed using two clinician-rated scoring instruments, Hamilton's Anxiety Scale (HAM-A) and Montgomery-Åsberg's Depression Rating Scale (MADRS), and a patient-rated scoring instrument, Beck's Depression Inventory (BDI). Results: At the end of the study no significant difference between groups in improvement of quality of life was found. A trend towards a superior improvement in glycemic control was found in the paroxetine group (p = 0.08). A superior increase in sex-hormone-binding-globuline (SHBG) levels was evidenced in the paroxetine group (p = 0.01) as a sign of improved insulin sensitivity. There was also a trend for superior efficacy of paroxetine in investigator-rated anxiety and depression. This notion was supported by a trend for superior decrease of serum cortisol levels in the paroxetine group (p = 0.06). Conclusion: Paroxetine has a beneficial effect on measures of insulin sensitivity and may improve glycemic control. Larger studies of longer duration are needed to verify the benefits of paroxetine in type 2 diabetes. While waiting for more conclusive evidence it seems sensible to augment standard care of type 2 diabetes with paroxetine even in patients who do not fulfil routine psychiatric criteria for initiation of antidepressant drug treatment.

引用

页码：1 / 6

页数：5

共 19 条

[1]

Harris M.I., Flegal K.M., Cowie C.C., Eberhardt M.S., Goldstein D.E., Little R.R., Wiedmeyer H.M., Byrd-Holt D.D., Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults: The Third National Health and Nutrition Examination Survey, 1988-94, Diabetes Care, 21, pp. 518-524, (1998)

[2]

Nelson R.G., Everhart J.E., Knowler W.C., Bennett P.H., Incidence, prevalence, and risk factors for non-insulin dependent diabetes mellitus, Primary Care, 15, pp. 227-250, (1988)

[3]

Golay A., Felber J.P., Dusmet M., Gomez F., Curchod B., Jequier E., Effect of weight loss on glucose disposal in obese and obese diabetic patients, Int J Obes, 9, pp. 181-190, (1985)

[4]

O'Kane M., Wiles P.G., Wales J.K., Fluoxetine in the treatment of obese type 2 diabetic patients, Diabetic Med, 11, pp. 105-110, (1994)

[5]

Gray D.S., Fujioka K., Devine W., Bray G.A., A randomized double-blind clinical trial of fluoxetine in obese diabetics, Int J Obes Relat Metab Disord, 16, SUPPL. 4, (1992)

[6]

Levine L.R., Enas G.G., Thompson W.L., Byyny R.L., Dauer A.D., Kirby R.W., Kreindler T.G., Levy B., Lucas C.P., McIlwain H.H., Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: A dose-response study, Int J Obes, 13, pp. 635-645, (1989)

[7]

Maheux P., Ducros F., Bourque J., Garon J., Chiasson J.L., Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss, Int J Obes Relat Metab Disord, 21, pp. 97-102, (1997)

[8]

Gavard J.A., Lustman P.J., Clouse R.E., Prevalence of depression in adults with diabetes: An epidemiological evaluation, Diabetes Care, 16, pp. 1167-1178, (1993)

[9]

Goodnick P.J., Kumar A., Henry J.H., Buki V.M., Goldberg R.B., Sertraline in coexisting major depression and diabetes mellitus, Psychopharmacol Bull, 33, pp. 261-264, (1997)

[10]

Gjerris A., Bech P., Bojholm S., Rafaelsen O.J., The Hamilton Anxiety Scale, J Affect Dis, 5, pp. 163-170, (1983)

← 1 2 →